iRhythm Holdings (IRTC) Following Zio And AI Growth Narrative Faces A Valuation Question
Recent trading in iRhythm Holdings (IRTC) has caught investor attention, with the stock closing at US$112.55 and posting declines over the past week, month, and past 3 months, raising questions about how current pricing aligns with fundamentals.
See our latest analysis for iRhythm Holdings.
For context, iRhythm Holdings’ recent 1 day share price decline of 5.17% and 7 day share price decline of 10.02% sit against a year to date share price return that is down 35.77%, while the 5 year total shareholder return of 114.59% points to a very different longer term picture.
If recent moves in iRhythm Holdings have you reassessing your watchlist, it could be a good time to cast a wider net with our healthcare focused screener of 40 healthcare AI stocks
With iRhythm Holdings now trading at US$112.55 against a wide spread of valuation estimates centered near US$177, the key issue is whether the recent share price slide has pushed the stock below fair value.
Most Popular Narrative: 37.1% Undervalued
The most widely followed narrative currently points to a fair value of about $178.93 for iRhythm Holdings versus the last close at $112.55, putting a spotlight on the growth and profitability assumptions behind that gap.
Investment in the Zio ecosystem including next-generation patches, enhanced form factors, and AI-powered analytics (such as the Lucem Health partnership) is improving product differentiation, diagnostic yield, and workflow efficiency, likely leading to higher gross margins and operating leverage as software and data become a larger component of the business.
Want to understand why this narrative assigns such a premium to iRhythm Holdings? The entire case turns on ambitious revenue expansion, margin uplift, and a rich future earnings multiple. Curious which assumptions really move that $178.93 fair value and how sensitive it is to even small changes in growth expectations?
Result: Fair Value of $178.93 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors in iRhythm Holdings still face meaningful risks if regulatory costs climb further, or if competition and new monitoring technologies pressure margins and growth expectations.
Find out about the key risks to this iRhythm Holdings narrative.
Another View on iRhythm Holdings’ Valuation
While the analyst narrative points to a fair value of $178.93 for iRhythm Holdings and frames the stock as undervalued, the current P/S ratio of 4.7x looks higher than both the US Medical Equipment industry average of 2.8x and the peer average of 3.7x, and even sits above a fair ratio of 4.3x. This raises the question of whether investors are already paying up for the growth story.
For a closer look at how this pricing gap lines up against fundamentals and sector peers, take a moment to review the See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mixed picture around iRhythm Holdings leaves you undecided, use the data to evaluate the situation quickly and form your own stance with 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond iRhythm Holdings?
If iRhythm Holdings has sharpened your focus, now is the moment to broaden your opportunity set with other stocks that fit clear, disciplined criteria.
- Target potential mispricings by scanning 44 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their underlying strength.
- Strengthen your income stream by reviewing 8 dividend fortresses built around companies offering higher yields with a focus on durability.
- Protect your capital by focusing on resilience first with the 79 resilient stocks with low risk scores, highlighting stocks with lower overall risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com